Title:
FUSED AZATRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE
Document Type and Number:
WIPO Patent Application WO/2022/166810
Kind Code:
A1
Abstract:
The present disclosure relates to a fused azatricyclic derivative, a preparation method therefor, and an application thereof in medicine. In particular, the present disclosure relates to a fused azatricyclic derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing said derivative, and a use thereof as a therapeutic agent, in particular a use as a GR modulator and a use in the preparation of a drug for the treatment and/or prevention of tumors.
More Like This:
Inventors:
LI XIN (CN)
ZHONG JIAXIN (CN)
CAI GUODONG (CN)
HE FENG (CN)
TAO WEIKANG (CN)
ZHONG JIAXIN (CN)
CAI GUODONG (CN)
HE FENG (CN)
TAO WEIKANG (CN)
Application Number:
PCT/CN2022/074588
Publication Date:
August 11, 2022
Filing Date:
January 28, 2022
Export Citation:
Assignee:
JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/4162; C07D471/04; A61P5/44
Domestic Patent References:
| WO2020172501A1 | 2020-08-27 |
Foreign References:
| CN106029066A | 2016-10-12 | |||
| CN104619328A | 2015-05-13 | |||
| CN101027301A | 2007-08-29 |
Other References:
HUNT HAZEL J., BELANOFF JOSEPH K., GOLDING EMILY, GOURDET BENOIT, PHILLIPS TIMOTHY, SWIFT DENISE, THOMAS JENNIFER, UNITT JOHN F., : "1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 25, no. 24, 1 December 2015 (2015-12-01), Amsterdam NL , pages 5720 - 5725, XP055945419, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2015.10.097
HUNT, H. J. ET AL. .: "Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)- 4, 4a, 5, 6, 7, 8-hexahydro-1H-pyrazolo[3, 4-g]isoquinolin-4a-yl)(4- (trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist", J. MED. CHEM., vol. 60, 3 April 2017 (2017-04-03), XP055404285, DOI: 10.1021/acs.jmedchem.7b00162
HUNT, H. J. ET AL. .: "Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)- 4, 4a, 5, 6, 7, 8-hexahydro-1H-pyrazolo[3, 4-g]isoquinolin-4a-yl)(4- (trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist", J. MED. CHEM., vol. 60, 3 April 2017 (2017-04-03), XP055404285, DOI: 10.1021/acs.jmedchem.7b00162
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: